Therefore, Chen et al. developed an adjusted prognosis analysis (APA) model for evaluating individuals initially diagnosed with NSCLC and BM, and included the following six prognostic factors: KPS, age, smoking history (replaced by epidermal growth factor receptor (EGFR) mutation in APA 2), local treatment of intracranial metastases, EGFR‐tyrosine kinase inhibitor (TKI) treatment, and chemotherapy,8 which seems to be more advantageous than RPA and GPA. Here, EGFR is linked to non-small cell lung carcinoma.